DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
ND0612 is an investigational drug.
There have been 9 clinical trials for ND0612. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2016.
The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are NeuroDerm Ltd., Quotient Clinical, and Michael J. Fox Foundation for Parkinson's Research.
There are twenty-three US patents protecting this investigational drug and one hundred and sixty-nine international patents.
Recent Clinical Trials for ND0612
|A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).||NeuroDerm Ltd.||Phase 3|
|A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations||NeuroDerm Ltd.||Phase 3|
|A Clinical Study Investigating Long Term Safety of ND0612, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease||NeuroDerm Ltd.||Phase 2|
Top disease conditions for ND0612
Top clinical trial sponsors for ND0612
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ND0612||Start Trial||Dopa decarboxylase inhibitor compositions||NeuroDerm, Ltd. (Rehovot, IL)||Start Trial|
|ND0612||Start Trial||Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof||LobSor Pharmaceuticals Aktiebolag (Knivsta, SE)||Start Trial|
|ND0612||Start Trial||Anti-nausea drug combinations||Start Trial|
|ND0612||Start Trial||Melt-extruded release controlled pharmaceutical composition and oral dosage form comprising the same||Samyang Biopharmaceutical Corporation (Seoul, KR)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|ND0612||European Patent Office||3116475||2034-03-13||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|